|
tipas |
leidinys |
| 3 |
Žurnalas |
Trissel LA, Martinez JF.
Compatibility of amifostine with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 2208-2212. |
| 59 |
Žurnalas |
Trissel LA, Gilbert DL, Martinez JF, Kim MC.
Compatibility of remifentanil hydrochloride with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 2192-2196. |
| 62 |
Žurnalas |
Pugh CB, Pabis DJ, Rodriguez C.
Visual compatibility of morphine sulfate and meperidine hydrochloride with other injectable drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 123-125. |
| 77 |
Žurnalas |
Shea BF, Souney PF.
Stability of famotidine frozen in polypropylene syringes.
Am J Hosp Pharm 1990 ; 47: 2073-2074. |
| 81 |
Žurnalas |
Trissel LA, Martinez JF.
Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 672-678. |
| 84 |
Žurnalas |
Trissel LA, Martinez JF.
Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 495-499. |
| 99 |
Žurnalas |
Trissel LA, Martinez JF.
Compatibility of aztreonam with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 1086-1090. |
| 169 |
Žurnalas |
Trissel LA, Martinez JF.
Physical compatibility of melphalan with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1993 ; 50: 2359-2363. |
| 182 |
Žurnalas |
Trissel LA, Gilbert DL, Martinez JF.
Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 56-60. |
| 187 |
Žurnalas |
Olsen KM, Gurley BJ, Davis GA, Christensen R, Monaghan MS.
Stability of flumazenil with selected drugs in 5% dextrose injection.
Am J Hosp Pharm 1993 ; 50: 1907-1912. |
| 215 |
Žurnalas |
Keyi X, Gagnon N, Bisson C, Desmarais M, LeBel M.
Stability of famotidine in polyvinyl chloride minibags and polypropylene syringes and compatibility of famotidine with selected drugs.
Ann Pharmacotherapy 1993 ; 27: 422-426. |
| 237 |
Žurnalas |
Lee DKT, Wong CY, Wang DP, Chang LC, Wu KH.
Stability of cefmetazole and famotidine.
Am J Health-Syst Pharm 1996 ; 53: 432. |
| 244 |
Žurnalas |
Trissel LA, Martinez JF.
Compatibility of filgrastim with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1907-1913. |
| 248 |
Žurnalas |
Trissel LA, Martinez JF.
Turbidimetric assessment of the compatibility of taxol with 42 other drugs during simulated Y-site injection.
Am J Hosp Pharm 1993 ; 50: 300-304. |
| 249 |
Žurnalas |
Trissel LA, Martinez JF.
Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1996 ; 53: 1041-1045. |
| 251 |
Žurnalas |
Trissel LA, Gilbert DL, Martinez JF.
Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 2708-2713. |
| 299 |
Žurnalas |
Trissel LA, Martinez JF, Gilbert DL.
Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1735-1741. |
| 300 |
Žurnalas |
Trissel LA, Gilbert DL, Martinez JF.
Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1287-1292. |
| 301 |
Žurnalas |
Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM.
Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1295-1300. |
| 307 |
Žurnalas |
Trissel LA, Martinez JF.
Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1792-1799. |
| 334 |
Žurnalas |
Trissel LA, Tramonte SM, Grilley BJ.
Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 988-992. |
| 335 |
Žurnalas |
Trissel LA, Bready BB, Kwan JW, Santiago NM.
Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection.
Am J Hosp Pharm 1992 ; 49: 402-406. |
| 354 |
Žurnalas |
Montoro JB, Pou L, Salvador P, Pastor C, Cano SM.
Stability of famotidine 20 and 40 mg/L in total nutrient admixtures.
Am J Hosp Pharm 1989 ; 46: 2329-2332. |
| 355 |
Žurnalas |
Bullock L, Fitzgerald JF, Glick MR.
Stability of famotidine 20 and 50 mg/L in total nutrient admixtures.
Am J Hosp Pharm 1989 ; 46: 2326-2329. |
| 356 |
Žurnalas |
Bullock LS, Fitzgerald JF, Glick MR, Parks RB, Schnabel JG, Hancock BG.
Stability of famotidine 20 and 40 mg/L and amino acids in total parenteral nutrient solutions.
Am J Hosp Pharm 1989 ; 46: 2321-2325. |
| 394 |
Žurnalas |
DiStefano JE, Mitrano FP, Baptista RJ, Der MM, Silvestri Ap, Palombo JD, Bistrian BR.
Long-term stability of famotidine 20 mg/L in a total parenteral nutrient solution.
Am J Hosp Pharm 1989 ; 46: 2333-2335. |
| 397 |
Žurnalas |
Fong PA, Ward J.
Visual compatibility of intravenous famotidine with selected drugs.
Am J Hosp Pharm 1989 ; 46: 125-126. |
| 398 |
Žurnalas |
Jay GT, Fanikos J, Souney PF.
Visual compatibility of famotidine with commonly used critical-care medications during simulated Y-site injection.
Am J Hosp Pharm 1988 ; 45: 1556-1557. |
| 403 |
Žurnalas |
Outman WR, Monolakis J.
Visual compatibility of haloperidol lactate with 0.9% sodium chloride injection or injectable critical-care drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 1539-1541. |
| 492 |
Žurnalas |
Trissel LA, Parks NPT, Santiago NM.
Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 2186-2189. |
| 496 |
Žurnalas |
Lor E, Sheybani T, Takagi J.
Visual compatibility of fluconazole with commonly used injectable drugs during simulated Y-site administration.
Am J Hosp Pharm 1991 ; 48: 744-746. |
| 522 |
Žurnalas |
Walker SE, Iazetta J, Lau DWC, Madorin PL.
Famotidine stability in total parenteral nutrient solutions.
Can J Hosp Pharm 1989 ; 42: 97-103. |
| 553 |
Žurnalas |
Bullock LS, Fitzgerald JF, Glick MR.
Stability of famotidine in minibags refrigerated and/or frozen.
Ann Pharmacotherapy 1989 ; 23: 132-135. |
| 660 |
Žurnalas |
Michaels MR, Stauffer GL, Haas DP.
Propofol compatibility with other intravenous drug products - Two new methods of evaluating IV emulsion compatibility.
Ann Pharmacotherapy 1996 ; 30: 228-232. |
| 687 |
Žurnalas |
Shea BF, Souney PF.
Stability of famotidine in a 3-in-1 total nutrient admixture.
Ann Pharmacotherapy 1990 ; 24: 232-235. |
| 690 |
Žurnalas |
Bullock LS, Fitzgerald JF, Mazur HI.
Stability of intravenous famotidine stored in polyvinyl chloride syringes.
Ann Pharmacotherapy 1989 ; 23: 588-590. |
| 693 |
Žurnalas |
Das Gupta V, Parasrampuria J, Bethea C.
Chemical stabilities of famotidine and ranitidine hydrochloride in intravenous admixtures.
J Clin Pharm Ther 1988 ; 13: 329-334. |
| 905 |
Žurnalas |
Trissel LA, Martinez JF.
Screening teniposide for Y-site physical incompatibilities.
Hosp Pharm 1994 ; 29: 1010-1017. |
| 921 |
Žurnalas |
Trissel LA, Gilbert DL, Martinez JF.
Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration.
Hosp Pharm 1998 ; 33: 284-292. |
| 1315 |
Žurnalas |
Halpern NA, Colucci RD, Alicea M, Greenstein R.
Visual compatibility of enalaprilat with commonly used critical care medications during simulated Y-site injection.
Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 294-297. |
| 1410 |
Žurnalas |
Trissel LA, Martinez JF, Simmons M.
Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 141-145. |
| 1415 |
Žurnalas |
Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M.
Compatibility of medications with 3-in-1 parenteral nutrition admixtures.
JPEN 1999 ; 23: 67-74. |
| 1420 |
Žurnalas |
Bergquist PA, Hunke WA, Reed RA, Manas D, Forsyth RJ, Kenney RR, Cook J, Holahan M.
Compatibility of tirofiban HCl with dopamine HCl, famotidine, sodium heparin, lidocaine HCl and potassium chloride during simulated Y-site administration.
J Clin Pharm Ther 1999 ; 24: 125-132. |
| 1423 |
Žurnalas |
Trissel LA, Martinez JF, Gilbert DL.
Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 514-518. |
| 1490 |
Žurnalas |
Halpern NA, Colucci RD, Alicea M, Greenstein R.
The compatibility of nicardipine hydrochloride injection with various ICU medications during simulated Y-site injection.
Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 250-254. |
| 1496 |
Žurnalas |
Trissel LA, Martinez JF, Gilbert DL.
Screening cladribine for Y-site physical compatibility with selected drugs.
Hosp Pharm 1996 ; 31: 1425-1428. |
| 1512 |
Laboratorija |
Tirofiban (Aggrastat®) - Summary of Product Characteristics
Beacon Pharmaceuticals Ltd 2015 |
| 1611 |
Žurnalas |
Chalmers JR, Bobek MB, Militello MA.
Visual compatibility of amiodarone hydrochloride injection with various intravenous drugs.
Am J Health-Syst Pharm 2001 ; 58: 504-506. |
| 1625 |
Žurnalas |
Trissel LA, Saenz C, Williams YW, Ingram D.
Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration.
Int J Pharm Compound 2001 ; 5: 314-321. |
| 1662 |
Žurnalas |
Trissel LA, Saenz CA, Ingram DS, Ogundele AB.
Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs.
J Oncol Pharm Practice 2002 ; 8: 33-37. |
| 1703 |
Žurnalas |
Schuster F, Bernard R.
Kompatibilität von enalaprilat i.v. mit ausgewählten arzneimitteln.
Krankenhauspharmazie 1995 ; 16: 101-103. |
| 1712 |
Žurnalas |
Trissel LA, Saenz CA.
Compatibility screening of Precedex during simulated Y-site administration with other drugs.
Int J Pharm Compound 2002 ; 6: 230-233. |
| 1713 |
Žurnalas |
Trissel LA, Saenz CA.
Compatibility screening of bivalirudin during simulated Y-site administration with other drugs.
Int J Pharm Compound 2002 ; 6: 311-315. |
| 1721 |
Žurnalas |
Trissel LA, Williams KY, Baker MB.
Compatibility screening of Hextend during simulated Y-site administration with other drugs.
Int J Pharm Compound 2001 ; 5: 69-72. |
| 1748 |
Žurnalas |
Wang DP, Wang MT, Wong CY, Lee DKT.
Compatibility of vancomycin hydrochloride and famotidine in 5% dextrose injection.
Int J Pharm Compound 1997 ; 1: 354-355. |
| 1754 |
Žurnalas |
Trissel LA, Gilbert DL, Wolkin AC.
Compatibility of docetaxel with selected drugs during simulated Y-site administration.
Int J Pharm Compound 1999 ; 3: 241-244. |
| 1800 |
Žurnalas |
Voytilla KL, Tyler LS, Rusho WJ.
Visual compatibility of azithromycin with 24 commonly used drugs during simulated Y-site delivery.
Am J Health-Syst Pharm 2002 ; 59: 853-855. |
| 1803 |
Žurnalas |
Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB.
Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2003 ; 60: 80-85. |
| 1925 |
Žurnalas |
Trissel LA , Williams KY, Gilbert DL.
Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions.
J Am Pharm Assoc 2000 ; 40: 515-519. |
| 1953 |
Žurnalas |
Trissel LA, Saenz CA, Ogundele AB, Ingram DS.
Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2004 ; 61: 2289-2293. |
| 1982 |
Žurnalas |
Trissel LA, Ogundele AB.
Compatibility of anidulafungin with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2005 ; 62: 834-837. |
| 2166 |
Žurnalas |
Nassr S, Dubuc MC, Lavoie P, Brazier JL.
HPLC-DAD methods for studying the stability of solutions containing hydromorphone, ketorolac, haloperidol, midazolam, famotidine, metoclopramide, dimenhydrinate and scopolamine.
J Liquid Chrom Rel Technol 2003 ; 26, 17: 2909-2929. |
| 2233 |
Žurnalas |
Condie C.K, Tyler L.S, Barker B, Canann D.M.
Visual compatibility of caspofungin acetate with commonly used drugs during simulated Y-site delivery
Am J Health-Syst Pharm 2008 ; 65, 5: 454-457. |
| 2262 |
Žurnalas |
Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D.
Compatibility of doripenem with other drugs during simulated Y-site administratioN
Am J Health-Syst Pharm 2008 ; 65: 1261-1265. |
| 2269 |
Žurnalas |
Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H.
Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551. |
| 2279 |
Žurnalas |
Kupiec T, Trusley C, Ben M, Trissel LA.
Physical and chemical stability of palonosetron hydrochloride with five common parenteral drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2008 ; 65, 18: 1735-1759. |
| 3152 |
Žurnalas |
Kumar A, Mann HJ.
Visual compatibility of oritavancin diphosphate with selected coadministered drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2010 ; 67: 1640-1644. |
| 3249 |
Žurnalas |
Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB.
Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2011 ; 68: 2163-2169. |
| 3254 |
Žurnalas |
Housman S.T, Tessier P.R, Nicolau D.P, Kuti J.L.
Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration
Am J Health-Syst Pharm 2011 ; 68: 2265-2270. |
| 3539 |
Laboratorija |
Bivalirudin (Angiox®) - Summary of Product Characteristics.
The Medecines Company 2013 |
| 3564 |
Laboratorija |
Rocuronium B Braun - Résumé des caractéristiques du produit.
B Braun 2012 |
| 3824 |
Žurnalas |
Boudi S, Roy H, Forest JM, Leclair G.
Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y.
Pharmactuel 2023 2023;56,3:91-98 |
| 3827 |
plakatas |
Ghazi I.M, Hamada Y, Nicolau D.P.
Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions.
ASHP Midyear 2015 |
| 3828 |
plakatas |
Thabit A.K, Hamada Y, Nicolau D.P.
Ceftozolane/tazobactam physical compatibility during simulated Y-site administration.
ASHP Midyear 2015 |
| 3829 |
plakatas |
So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L.
Compatibility of isavunazonium sulfate during simulated Y-site administration.
ASHP Midyear 2015 |
| 4055 |
Žurnalas |
Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D.
Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2018 , 75, 1:36-44 |
| 4145 |
Žurnalas |
Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P.
Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2018 ;75,14:1048-1056 |
| 4380 |
Laboratorija |
Posaconazole (Noxafil®) - Summary of Product Characteristics
Merck Sharp & Dohme Limited 2019 |
| 4433 |
Žurnalas |
Ghazi I.M, El Nekidy W.S, Sood A, Dulku A, Patel R, Patel K.
Y-site Administration of Imipenem/Cilastatin/ Relebactam With Common Intravenous Medications
Clin Ther 2020 ; 42, 3: 475-485. |
| 4507 |
Žurnalas |
Ross E, Salinas A, Petty K, Her C, Carpenter J.
Compatibility of medications with intravenous lipid emulsions: Effects of simulated Y-site mixing.
Am J Health-Syst Pharm 2020 ;77,23:1980-1985 |
| 4528 |
Žurnalas |
Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N.
Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration.
Int J Pharm Compound 2021 ;25,1:52-61 |
| 4650 |
Laboratorija |
Ceftobiprole (Zevtera 500 mg powder for concentrate for solution for infusion.) Summary of Product Characteristics, Advanz Pharma updated 4 aug 2021.
Advanz Pharma 2021 |
| 4742 |
Žurnalas |
Macoviciuc M, Nguyen C, Forest J-M, Leclair G.
Compatibilité physique de l’acétaminophène injectable avec 102 autres médicaments lors d’une administration en Y.
Pharmactuel 2022 ; 55, 4: 247-255. |
| 4801 |
Žurnalas |
Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J.
Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2024 ;51,1: |
